View Clinical Trial (Medical Research Study)

A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation - NCT01100151-91105(Clinical Trial 649782)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Pasadena
State:  
CA
Zip Code: 91105
Conditions: Opioid-induced Constipation
Purpose: The purpose of this study is to assess the safety and tolerability of RDC-1036 (ALKS 37) in adults with opioid-induced constipation following repeat dose administration
Study summary: Approximately 60 subjects will be enrolled in 1 of 2 cohorts. Following a review of Cohort 1 safety and tolerability data, subjects will then be enrolled into Cohort 2, to explore additional doses. Dose escalation will occur in both cohorts. There will be 18 visits over a 6-week period.
Criteria: Inclusion Criteria: - 18 to 70 years of age - BMI of 19 to 35 kg/m2 at screening - Receiving prescribed opioid medication for the management of chronic, non-cancer, pain - Diagnosis of opioid-induced constipation (OIC) - Willingness to stop all laxatives and other bowel regimens from the first study visit following screening until the end of the study. The use of constipation rescue medication will be allowed during the study. Exclusion Criteria: - Pregnancy and/or currently breastfeeding - Clinically significant medical condition or illness (other than the condition for which the pain medication is being prescribed) - Receiving treatment with opioid therapy for cancer-related pain, abdominal pain, scleroderma, and/or for the management of drug addiction - Any GI or pelvic disorder known to affect bowel transit, produce a GI obstruction, or contribute to bowel dysfunction other than opioid-induced constipation (eg, diverticulitis, other intestinal strictures, bezoars) - Use of medical devices such as pacemakers, infusion pumps, or insulin pumps - Use of naloxone, Subutex or Suboxone, Revia, Relistor, or Entereg starting 15 days before the first study visit following screening until the end of the study - Participation in a clinical trial of a pharmacological agent within 30 days before screening
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: October 23, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.